Sentinel lymph node biopsy (SLNB)
Considerations
History
2009: Head and neck sentinel lymph node biopsy: current state of the art
Cutaneous melanoma
Indications
All patients with clinically negative nodal basin and a primary melanoma greater than 1 mm in depth
The National Comprehensive Cancer Network (NCCN) currently recommends against SLND for melanoma in situ or melanoma less than 1.0 mm in thickness
May be considered for melanoma 0.76-1.0 mm in thickness if adverse features (ulceration, increased mitotic rate, positive deep margins, lymphovascular invasion, age < 40 years, significant vertical growth phase, Clark level ≥IV) are present
May be considered for melanoma that exhibits regression (controversial)
2009: Sentinel lymph node biopsy for melanoma: indications and rationale
"In our opinion, SLNB should be performed on most patients (with acceptable surgical and anesthesia risk) who have melanomas with a Breslow depth >or= 0.76 mm"
2011: Sentinel node biopsy for head and neck melanoma: a systematic review
2014: Sentinel Lymph Node Biopsy in Head and Neck Melanoma: A Review
2015: Is sentinel lymph node biopsy the standard of care for cutaneous head and neck melanoma?
Squamous cell carcinoma
2009: Sentinel node biopsy in head and neck squamous cell carcinoma
2014: Sentinel lymph node biopsy for oral cancer: supporting evidence and recent novel developments
Merkel cell carcinoma
2012: Role of Sentinel Lymph Node Biopsy in the Management of Merkel Cell Carcinoma
Other readings
2017: Management Controversies in Head and Neck Melanoma: A Systematic Review
Preparation
Nuclear Medicine suite for lymphoscintigraphy
Meet the technician, NM physician, and patient on the morning of the day of surgery
For dosing, see Dr. Rasgon's recommendations ***
2009: Lymphoscintigraphy in cutaneous melanoma: an updated total body atlas of sentinel node mapping
2015: EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma
Equipment
Ultrasound
Methylene blue
TB syringe and *** needle
Neoprobe Gamma Detection System (GTS) with collimator (YouTube 0:21 - Neoprobe In-Service Video: Technician Focus - Collimator)
Tray ***
Inspect, palpate, and mark the primary tumor
Inspect, palpate, scan with Neoprobe, ultrasound, and mark suspect sentinel lymph nodes(s)
Procedure
Infiltrate Methylene blue intradermally at 4 points around the gross margin of the primary tumor
Infiltrate local anesthesia
Prep and drape
Complete wide local excision of the primary tumor
Orient for permanent pathology
Scan the wound bed
Identify the potential SLN with the highest gamma count
Dissect and remove the first SLN
Measure the gamma count of the first SLN ex vivo and record this value
Repeat scan the wound bed
If the background gamma count is less than 10% of the "hottest" (highest count) SLN ex vivo then cease the dissection
If not, then continue to dissect and remove additional SLNs
Sample operative report
Post-op
Pearls & Pitfalls
Plan all SLNB incisions being mindful that a completion neck dissection or parotidectomy may be necessary in the future